Immunogenicity of biologic therapies: causes and consequences

References

• https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm
   Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. MAb. 2018 January;4:183–203.
   Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Wei SC, Chang TA, Chao TH, et al. Management of crohn’s disease in Taiwan: consensus guideline of the taiwan society of inflammatory bowel disease. Intest Res. 2017;15(3):285–310.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis. JDDG. 2018. In press.
   Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2017 November 1. 10.1111/bjd.16102. [Epub ahead of print].
   Google Scholar
• De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673–1682. Ann Rheum Dis. 2013 Feb;72(2):165–78. doi:10.1136/annrheumdis-2012-202545. Epub 2012 Nov 24.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–178.
   PubMed Web of Science ®Google Scholar
• Kalden JR, Schulze-Koops H. Immunogenicity and loss of responset o TNF inhibitors: implications for rheumatoid arthritis treatment. Nature Reviews Rheumatology. 2017;13(12):707–718.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–172.
   PubMed Web of Science ®Google Scholar
• Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. Mabs. 2016;8(3):536–550.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9(10):767–774.
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36(1):3–10.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Feb 15]. http://www.who.int/medicines/services/inn/Generalpoliciesformonoclonalantibodies2009.pdf
   Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211–215.
   PubMed Web of Science ®Google Scholar
• Christen U, Thuerkauf R, Stevens R, et al. Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum Immunol. 1999;60(9):774–790.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 2013;30(7):1729–1734.
   PubMed Web of Science ®Google Scholar
• Parenky A, Myler H, Amaravadi L, et al. New FDA draft guidance on immunogenicity. Aaps J. 2014;16(3):499–503.
   PubMed Web of Science ®Google Scholar
• Müller-Ladner U, Hong S, Oh C, et al. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. Expert Rev Clin Immunol. 2015;11(Suppl 1):S5–14.
   PubMedGoogle Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. London: EMEA. http://www.ema.europa.eu/docs/en_GB/document_linbrary/scientific_guideline/2012/06/WC500128686.pdf
   Google Scholar
• Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol. 2015;135(1):31–38.
   PubMed Web of Science ®Google Scholar
• Krintel SB, Grunert VP, Hetland ML, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology. 2013;52(7):1245–1253.
   PubMed Web of Science ®Google Scholar
• Hoxha A, Calligaro A, Tonello M, et al. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Joint Bone Spine. 2016;83(2):167–171.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
   PubMed Web of Science ®Google Scholar
• Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176(3):752–758.
   PubMed Web of Science ®Google Scholar
• Bae SC, Kim J, Choe JY, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis. 2017;76(1):65–71.
   PubMed Web of Science ®Google Scholar
• Lambert J, Nast A, Nestle FO, et al. Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: what can be learnt from other diseases? J Dermatolog Treat. 2015;26(6):520–527.
   PubMed Web of Science ®Google Scholar
• Keiserman M, Codreanu C, Handa R, et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol. 2014;10(8):1049–1057.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457.
   PubMed Web of Science ®Google Scholar
• Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267–1281.
   PubMed Web of Science ®Google Scholar
• Hart MH, De Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372(1–2):196–203.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–88.
   PubMed Web of Science ®Google Scholar
• Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306–311.
   PubMed Web of Science ®Google Scholar
• Hong DI, Bankova L, Cahill KN, et al. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol. 2012;8(1):43–52.
   PubMed Web of Science ®Google Scholar
• Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol. 2009;129(2):289–301.
   PubMed Web of Science ®Google Scholar
• Jullien D. Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis. Ann Dermatol Venereol. 2012;139(Suppl 2):S58–67.
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn’s disease: optimize not immunize. Gastroenterology. 2003;124(4):1140–1145.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126(2):402–413.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA; 2007. http://www.ema.eiropa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
   Google Scholar
• Food and Drug Administration. Immunogenicity assessment for therapeutic protein products. FDA (2013). [cited 2018 Feb 15]. (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf)
   Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69–74.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–1563.
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–1955.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Pouw MF, Nurmohamed M, et al. Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Ann Rheum Dis. 2015;74(2):474–475.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914–1915.
   PubMed Web of Science ®Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213–222.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Collier DH, Saunders KC, et al. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;1(1):e000181.
   PubMedGoogle Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Jama. 2011;305(14):1460–1468.
   PubMed Web of Science ®Google Scholar
• Jungedal R, Lundkvist M, Engdahl E, et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler. 2012;18(12):1775–1781.
   PubMed Web of Science ®Google Scholar
• Lundkvist Ryner M, Farrell RA, Fogdell-Hahn A. The case for measuring anti-drug antibodies in people with multiple sclerosis. Expert Rev Clin Immunol. 2014;10(6):697–699.
   PubMed Web of Science ®Google Scholar
• Garcês S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73(6):1138–1143.
   PubMed Web of Science ®Google Scholar
• van der Bijl AE, Breedveld FC, Antoni CE, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27(8):1021–1028.
   PubMed Web of Science ®Google Scholar
• Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20(10):1714–1721.
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75(9):1693–1696.
   PubMed Web of Science ®Google Scholar
• Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis. 2012;18(11):2026–2033.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–447.
   PubMed Web of Science ®Google Scholar
• Strik AS, van den Brink GR, Ponsioen C, et al. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128–1134.
   PubMed Web of Science ®Google Scholar
• Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann Allergy Asthma Immunol. 2016;117(2):115–120.
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–1266.
   PubMed Web of Science ®Google Scholar
• Galvão VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015r;3(2):175–185.
   PubMed Web of Science ®Google Scholar
• Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis–a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341–384.
   PubMed Web of Science ®Google Scholar